These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 12478112)

  • 1. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival.
    Shahin O; Thalmann GN; Rentsch C; Mazzucchelli L; Studer UE
    J Urol; 2003 Jan; 169(1):96-100; discussion 100. PubMed ID: 12478112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term results of intravesical bacillus Calmette-Guérin therapy for stage T1 superficial bladder cancer.
    Brake M; Loertzer H; Horsch R; Keller H
    Urology; 2000 May; 55(5):673-8. PubMed ID: 10792077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of tumor-free status in repeat resection before intravesical bacillus Calmette-Guerin for high grade Ta, T1 and CIS bladder cancer.
    Guevara A; Salomon L; Allory Y; Ploussard G; de la Taille A; Paul A; Yiou R; Hoznek A; Dahan M; Abbou CC; Vordos D
    J Urol; 2010 Jun; 183(6):2161-4. PubMed ID: 20399454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of time to second transurethral resection on oncological outcomes of patients with high-grade T1 bladder cancer treated with intravesical Bacillus Calmette-Guerin.
    Calò B; Falagario U; Sanguedolce F; Veccia A; Chirico M; Carvalho-Diaz E; Mota P; Lima E; Autorino R; Carrieri G; Cormio L
    World J Urol; 2020 Dec; 38(12):3161-3167. PubMed ID: 32062805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
    Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M
    J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.
    Lebret T; Bohin D; Kassardjian Z; Herve JM; Molinie V; Barre P; Lugagne PM; Botto H
    J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial.
    Martínez-Piñeiro JA; Martínez-Piñeiro L; Solsona E; Rodríguez RH; Gómez JM; Martín MG; Molina JR; Collado AG; Flores N; Isorna S; Pertusa C; Rabadán M; Astobieta A; Camacho JE; Arribas S; Madero R;
    J Urol; 2005 Oct; 174(4 Pt 1):1242-7. PubMed ID: 16145378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
    Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
    Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guérin.
    Skinner EC; Goldman B; Sakr WA; Petrylak DP; Lenz HJ; Lee CT; Wilson SS; Benson M; Lerner SP; Tangen CM; Thompson IM
    J Urol; 2013 Oct; 190(4):1200-4. PubMed ID: 23597452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor.
    Ferro M; Di Lorenzo G; Vartolomei MD; Bruzzese D; Cantiello F; Lucarelli G; Musi G; Di Stasi S; Hurle R; Guazzoni G; Busetto GM; Gabriele A; Del Giudice F; Damiano R; Perri F; Perdona S; Verze P; Borghesi M; Schiavina R; Almeida GL; Bove P; Lima E; Autorino R; Crisan N; Farhan ARA; Battaglia M; Russo GI; Ieluzzi V; Morgia G; De Placido P; Terracciano D; Cimmino A; Scafuri L; Mirone V; De Cobelli O; Shariat S; Sonpavde G; Buonerba C
    World J Urol; 2020 Jan; 38(1):143-150. PubMed ID: 30993426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrence and progression of T1G3 transitional cell carcinoma of the bladder treated with intravesical bacillus Calmette-Guérin.
    Günlüsoy B; Değirmenci T; Arslan M; Nergiz N; Minareci S; Ayder AR
    Urol Int; 2005; 75(2):107-13. PubMed ID: 16123562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravesical bacille Calmette-Guérin in Stage T1 grade 3 bladder cancer therapy: a 7-year follow-up.
    Hurle R; Losa A; Manzetti A; Lembo A
    Urology; 1999 Aug; 54(2):258-63. PubMed ID: 10443721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder.
    Sylvester RJ; Brausi MA; Kirkels WJ; Hoeltl W; Calais Da Silva F; Powell PH; Prescott S; Kirkali Z; van de Beek C; Gorlia T; de Reijke TM;
    Eur Urol; 2010 May; 57(5):766-73. PubMed ID: 20034729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy: Implication for Clinical Trial Design.
    Mmeje CO; Guo CC; Shah JB; Navai N; Grossman HB; Dinney CP; Kamat AM
    Eur Urol; 2016 Nov; 70(5):778-785. PubMed ID: 26922408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravesical bacillus Calmette-Guerin therapy after second transurethral resection for primary T1 bladder cancer.
    Baba M; Kageyama S; Yoshida T; Fujiwara R; Kim CJ; Takimoto K; Nagasawa M; Soga H; Nagatani Y; Nishikawa Z; Kawauchi A
    Int J Clin Oncol; 2018 Oct; 23(5):951-956. PubMed ID: 29761307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
    Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
    J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guérin.
    Sfakianos JP; Kim PH; Hakimi AA; Herr HW
    J Urol; 2014 Feb; 191(2):341-5. PubMed ID: 23973518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
    Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
    Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is it possible to stop follow-up of patients with primary T1G3 urothelial carcinoma of the bladder managed with intravesical bacille Calmette-Guérin immunotherapy?
    Golabek T; Palou J; Rodríguez O; Gaya JM; Breda A; Villavicencio H
    World J Urol; 2017 Feb; 35(2):237-243. PubMed ID: 27277599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravesical bacillus Calmette-Guérin treatment for Stage T1 grade 3 transitional cell carcinoma of the bladder.
    Baniel J; Grauss D; Engelstein D; Sella A
    Urology; 1998 Nov; 52(5):785-9. PubMed ID: 9801099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.